GBS in Newborns: Antibiotic-Resistant Strains Explained | Michigan State University Research

March 21, 2026 Ananya Mittal - World Editor

A recent study offers a potential explanation for why some newborns still contract Group B Streptococcus (GBS) infections despite their mothers receiving antibiotic treatment during labor. Researchers at Michigan State University have identified strains of GBS exhibiting a heightened mutation rate, allowing them to survive antibiotic exposure and potentially infect infants. This discovery, published in the journal mBio, marks the first time GBS has been classified as a “mutator” bacteria – one with a dramatically increased ability to evolve and adapt.

Understanding Group B Streptococcus and Newborn Risk

Group B Streptococcus is a common bacterium often found in the digestive and genital tracts of healthy individuals. Approximately one in three pregnant women carry GBS in their birth canal. Even as typically harmless to the mother, the bacteria can be transmitted to the baby during childbirth, posing a serious threat to newborns whose immune systems are still developing. Infections can manifest as pneumonia, meningitis, or sepsis – all potentially life-threatening conditions.

The introduction of preventative antibiotic treatment in the 1990s, involving screening pregnant women for GBS and administering antibiotics during labor if positive, significantly reduced the incidence of newborn GBS infections. But, cases continue to occur, prompting researchers to investigate why the standard treatment isn’t always effective. This new research suggests that the emergence of these “mutator” strains may be a key factor.

How Do These Mutant Strains Survive?

The Michigan State University team discovered that these postpartum GBS strains possess defects in their DNA repair machinery. This doesn’t make them immune to antibiotics directly, but it dramatically increases their mutation rate. Essentially, the bacteria are evolving much faster than usual, increasing the likelihood that some will develop characteristics that allow them to withstand the effects of antibiotics. As explained by Shannon Manning, the senior author of the study and a professor of microbiology, genetics, and immunology, “These bacteria are savvy, and they’ve adapted strategies to avoid getting killed by antibiotics — not in the ways we expected, but through other mechanisms.”

This adaptation isn’t about developing resistance to the antibiotic itself, but rather about finding alternative ways to survive in the hostile environment created by the treatment. The study doesn’t detail *which* specific mutations are conferring this survival advantage, but identifying these mutator strains is the crucial first step toward understanding the process.

What Does This Mean for Prevention and Treatment?

The findings don’t suggest a need to change current preventative measures immediately. The standard screening and antibiotic protocols remain the recommended course of action. However, this research opens new avenues for investigation. Understanding the specific mutations that allow these strains to survive could lead to the development of new drug targets or alternative treatment strategies.

Currently, the focus is on identifying these mutator strains and tracking their prevalence. Further research is needed to determine how widespread these strains are and how quickly they are evolving. The study’s authors emphasize that this is a complex issue, and a single solution is unlikely.

The History of GBS and Newborn Infections

Group B Streptococcus wasn’t widely recognized as a major threat to newborns until the 1970s. Before the implementation of preventative antibiotic treatment, GBS was a leading cause of illness and death in newborns, with over half of infected babies succumbing to the infection. The introduction of screening and antibiotic prophylaxis dramatically improved outcomes, but the continued occurrence of late-onset GBS disease – infections appearing after the first week of life – highlights the need for ongoing research and vigilance. You can find more information about GBS and its impact on newborns from the Centers for Disease Control and Prevention (CDC).

Limitations and Future Research Directions

It’s important to note that this study represents an early step in understanding the complexities of GBS infection. The research focused on postpartum strains, and further investigation is needed to determine whether similar mutator strains exist in other GBS populations. The study also doesn’t address the mechanisms by which these mutations are selected for or how they impact the severity of infection.

Future research will likely focus on:

  • Identifying the specific genetic mutations responsible for the increased mutation rate and antibiotic survival.
  • Determining the prevalence of these mutator strains in different populations and geographic regions.
  • Investigating the effectiveness of alternative treatment strategies against these strains.
  • Exploring the potential for developing new diagnostic tools to rapidly identify mutator strains.

Public Health Surveillance and Ongoing Monitoring

Effective surveillance systems are crucial for tracking the emergence and spread of antibiotic-resistant bacteria like GBS. Public health agencies, such as the CDC, continuously monitor GBS infection rates and analyze bacterial strains to identify trends and potential threats. This information is used to inform public health recommendations and guide research efforts. The EurekAlert! news release details the study’s findings and emphasizes the importance of continued monitoring.

The discovery of these GBS mutator strains underscores the ongoing challenge of combating antibiotic resistance. While current preventative measures remain effective for many, continued research and vigilance are essential to protect newborns from this potentially devastating infection. For concerned parents, the best course of action is to discuss any questions or concerns with their healthcare provider and stay informed about the latest public health recommendations. Additional information on GBS can be found at the National Center for Biotechnology Information.